It's the Bryant Mayer Show on WNYC.

Good morning again everyone.

Now we'll revisit a rapidly evolving topic

that continues to get so much attention culturally, medically,

and financially. The technical term is GLP1 agonist medications but they're more

commonly known by the brand names Ozempeck or Gove, or Manjaro, or by the active ingredients, semaglutide, a class of medication created

to treat diabetes, but they carry a socially desirable side effect, easy weight loss.

These drugs are seemingly everywhere,

as I don't have to tell you, yet incredibly elusive

in a certain way.

Maybe you've seen them advertised in subway cars in speculative conversations

about celebrities or you've personally discussed the pros and cons of

using these drugs with your doctor or use them yourselves on label or off.

Perhaps you've come across headlines describing revolutionary impacts like can weight

loss drugs such as Osempic also treat addiction and dementia from the Guardian.

We talked about that one or will the Osempic era change how we think about being

fat and being thin from the New Yorker.

We have the writer of that article on.

There's a New York Times story just today

about their potential for treating kidney disease.

But while the discussion is endless, the supply is not.

Limited supply and growing demand have made the brand name GLP1 medications

...